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ABSTRACT: Marine cyanobacteria (blue-green algae) have been shown to possess an enormous capacity to produce 
structurally diverse natural products that exhibit a broad spectrum of potent biological activities, including cytotoxic, 
antifungal, antiparasitic, antiviral and antibacterial activities. Using mass spectrometry-guided fractionation together 
with molecular networking, cyanobacterial field collections from American Samoa and Palmyra Atoll yielded three new 
cyclic peptides, tutuilamides A–C. Their structures were established by spectroscopic techniques including 1D and 2D 
NMR, HR-MS, and chemical derivatization. Structure elucidation was facilitated by employing advanced NMR techniques 
including non-uniform sampling in combination with the 1,1-ADEQUATE experiment. These cyclic peptides are charac-
terized by the presence of several unusual residues including 3-amino-6-hydroxy-2-piperidone and 2-amino-2-butenoic 
acid, together with a novel vinyl chloride-containing residue. Tutuilamides A-C show potent elastase inhibitory activity 
together with moderate potency in H-460 lung cancer cell cytotoxicity assays. The binding mode to elastase was analyzed 
by X-ray crystallography revealing a reversible binding mode similar to the natural product lyngbyastatin 7. The presence 
of an additional hydrogen bond with the amino acid backbone of the flexible side chain of tutuilamide A, compared to 
lyngbyastatin 7, facilitates its stabilization in the elastase binding pocket and possibly explains its enhanced inhibitory 
potency. 
INTRODUCTION 
Cyanobacteria produce a wide range of cyclic depsipep-
tides that contain an unusual 3-amino-6-hydroxy-2-
piperidone (Ahp) moiety; these peptides are generally 
referred to as cyanopeptolin-like peptides or Ahp-
cyclodepsipeptides.1–3 The general structure includes an 
amino acid chain of variable length of which six amino 
acid residues form a macrocyclic ring. Most cyanopep-
tolin-like peptides contain the Ahp residue and an ester 
linkage between the β-OH group of L-threonine and the 
carboxyl group of the C-terminal amino acid. Additional-
ly, among these Ahp containing peptides, there are more 
than 20 compounds that contain a highly conserved hex-
adepsipeptide core bearing an additional 2-amino-2-
butenoic acid (Abu) moiety adjacent to the Ahp ring to-
gether with a highly variable side chain (Table 1). 
Ahp-containing peptides have frequently been observed 
from both marine and freshwater cyanobacteria as well as 
other bacteria, and over 200 are now known.3 However, 
peptides containing the Abu moiety are generally found 
in marine bacteria, with the exception being 
stigonemapeptin which derives from a freshwater 
 
Table 1. Abu and Ahp-containing peptides isolated from Cyanobacteria. 
Compound name Year Collected from Isolated organism 
Dolastatin 135 1989 East Africa, Indian Ocean Dolabella auricularia (sea hare) 
Symplostatin 26 1999 Guam, Pago Bay Symploca hydnoides 
Somamide A+B7 2001 Fiji, Somo Somo Lyngbya majuscula / Schizothrix sp.  
Lyngbyastatin 48 2007 South Florida, Atlantic coast Lyngbya confervoides 
Lyngbyastatin 5–79 2007 South Florida, Fort Lauderdale / 
Florida Keys, Summerland Key 
Lyngbya confervoides 
Lyngbyastatin 8–1010 / Bouillomide A+B11 2009 Guam, Tumon Bay Lyngbya semiplena 
Molassamide12 2010 Florida, Molasses Reef  Dichothrix utahensis 
Stigonemapeptin4 2012 Wisconsin, North Nokomis Lake Stigonema sp. (freshwater) 
Symplostatin 5–1013 2013 Guam, Cetti Bay red Symploca sp. 
Kurahamide14 2014 Japan, Kuraha Lyngbya sp. assembly 
 
cyanobacterium (Table 1).4 Interestingly, the Abu moiety 
in stigonemapeptin is (E)-configured whereas the Abu 
moie-ties derived from marine sources are consistently 
(Z)-configured.X-ray crystallography of the elastase com-
plex formed with lyngbyastatin 7 (4) revealed that these 
Abu-cyclodepsipeptides act as substrate mimics.13 The 
Abu moiety was shown to occupy the S1 substrate binding 
pocket and engage in a non-covalent interaction. Addi-
tionally, a study of the binding mode of scyptolin showed 
that the Ahp moiety occupies a crucial part of the active 
site pocket and thereby prevents hydrolysis.15 It was sug-
gested that the Abu moiety increases the potency of these 
elastase inhibitors and that the pendant side chain is re-
sponsible for modulating their activity and selectivity.13 
In the current work, we report the isolation of three 
new members of this Ahp and Abu-containing family of 
peptides, named tutuilamides A (1) and B (2) based on the 
location of collection of the source cyanobacterium, 
Schizothrix sp., along with tutuilamide C (3) isolated from 
a Coleofasciculus sp. These structures were assembled by 
a combination of NMR, mass spectrometry (MS) and 
chromatographic analysis following acid hydrolysis and 
chiral derivatization, and feature an unusual vinyl chlo-
ride-containing residue never previously observed in this 
structure class. The new natural products, as well as two 
semisynthetic derivatives, were evaluated for serine pro-
tease inhibition and all of the cyclic species were found to 
be highly potent. The crystal structure of elastase in com-
plex with tutuilamide A revealed extensive binding inter-
actions in the substrate binding pocket, as has been 
shown previously with lyngbyastatin 7 (4). However, we 
identified additional hydrogen bond interactions between 
tutuilamide A and elastase that did not occur in the 
lyngbyastatin 7 co-crystal structure. These may be re-
sponsible for the increased potency of tutuilamide A 
compared to lyngbyastatin 7. 
 
RESULTS AND DISCUSSION 
Our discovery strategy to locate natural products with 
novel structural frameworks includes MS2-based metabo-
lomics (Molecular Networking) for strain selection and 
dereplication as well as chromatographic methods for 
isolation driven by structural features. Cyanobacterial 
colonies of the genus Schizothrix sp. and Coleofasciculus 
sp. were collected by hand from the main island of Tutui-
la in American Samoa in 2016 and Palmyra Atoll in 2008, 
respectively, using SCUBA gear. The crude CH2Cl2-MeOH 
(2:1) extract was initially fractionated using vacuum-liquid 
chromatography (VLC) as well as solid phase extraction 
(SPE) for further analysis by MS and NMR. This approach 
revealed the presence of peptides with unusual features 
and led to the HPLC isolation of tutuilamides A and B 
from Schizothrix sp and tutuilamide C from Coleofascicu-
lus sp. In addition, we identified related peptides such as 
symplostatin 2 together with several derivatives of dolas-
tatin 13 that have yet to be characterized. Tutuilamide A 
(1) and B (2) share the same cyclic peptide core and pos-
sess the unusual Ahp and Abu moieties. They differ by a 
single side chain residue wherein isoleucine is replaced by 
valine (Figure 1). Meanwhile, tutuilamide C (3) is an ana-
log of 2 that lacks an alanine moiety, but bears an addi-
tional methylene unit in the aliphatic side-chain. Moreo-
ver, they are the first cyanopeptolins to possess a vinyl 
chloride residue in the side chain. Vinyl chloride func-
tionalities in cyanobacteria have been shown to biosyn-
thetically result from a unique cassette of enzymes that 
involve polyketide synthase (PKS) beta branch formation 
along with radical-based chlorination of an intermediate, 
such as in jamaicamide A.16  
High-resolution electrospray ionization mass spec-
trometry (HR-ESI-MS) of tutuilamide A (1) displayed an 
ion peak at m/z 1043.4616 [M + Na]+ (calculated for 
C51H69ClN8O12Na, 1043.4616, Δ = 0.0 ppm), consistent with 
the molecular formula C51H69ClN8O12 containing 21 dou-
ble-bond equivalents. The isotope pattern for the molecu-
lar ion cluster indicated the clear presence of one chlorine 
atom. The 1H NMR spectrum of 1 in DMSO-d6 exhibited 
signals characteristic of a peptide including seven α-
proton signals at δ 4.65 (overlap), 4.89 (1H, dd, J = 11.5, 2.2 
Hz), 4.73 (1H, dd, J = 11.4, 4.0 Hz), 3.79 (1H, m), 4.67 (over-
lap), 4.40 (1H, t, J = 7.8 Hz), and 4.36 (1H, p, J = 7.2 Hz),  
 
 
Figure 1. Chemical structure of tutuilamide A (1), B (2) and C 
(3) together with the related lyngbyastatin 7 (4).9 
along with six amide NH signals at δ 7.53 (1H, t, J = 8.4 
Hz), 7.22 (1H, broad), 9.23 (1H, broad), 7.91 (1H, broad), 
and 8.21 (1H, d, J = 7.4 Hz) (Table S1). Additionally, a 
downfield pair of triplets at δ 7.18 (2H, t, J = 7.2 Hz) and 
7.15 (1H, t, J = 7.2 Hz) and a doublet at δ 6.83 (2H, d, J = 
7.2 Hz) were characteristic of a phenyl group; similarly, 
two doublets at δ 7.00 (2H, d, J = 8.3 Hz) and 6.78 (2H, d, 
J = 8.3 Hz) were characteristic for a para-substituted phe-
nol group. The proton NMR spectrum also showed a sin-
glet at δ 2.77 (3H, s), indicative of an N-methyl amide, 
together with eight partially overlapping methyl signals at 
δ 0.75 (3H, d, J = 6.8 Hz), δ 0.80 (3H, t, J = 7.5 Hz), δ 0.84 
(3H, d, J = 6.8 Hz), δ 0.88 (3H, d, J = 6.8 Hz), δ 1.19 (3H, d, 
J = 7.0 Hz), δ 1.21 (3H, d, J = 6.6 Hz), δ 1.48 (3H, d, J = 7.1 
Hz), and δ 1.72 (3H, d, J = 1.2 Hz). 
The HSQC spectrum revealed the presence of six meth-
ylene groups (δC-3Tyr 32.5, δH-3Tyr 3.11/2.69; δC-3Phe 35.2, 
δH-3Phe 2.88/1.83; δC-3Ahp 21.9, δH-3Ahp 2.42/1.58; δC-4Ahp 
29.2, δH-4Ahp 1.72/1.58; δC-4Ile 23.9, δH-4Ile 1.43/1.08; δC-
2Cmb 42.5, δH-2Cmb 2.97), two methines (δC-3Val 30.5, δH-
3Val 2.07; δC-3Ile 36.5, δH-3Ile 1.81), two oxygenated me-
thines (δC-5Ahp 73.7, δH-5Ahp 5.08; δC-3Thr 71.7, δH-3Thr 
5.53), and two vinylic methines (δC-3Abu 131.5, δH-3Abu 6.52; 
δC-4Cmb 114.3, δH-4Cmb 6.10). 
A detailed analysis of the 2D NMR data (HSQC, HMBC, 
and DQF-COSY) established the presence of valine, N-
methyl-tyrosine, phenylalanine, threonine, isoleucine and 
alanine together with an Ahp, an Abu and a 4-chloro-3-
methylbut-3-enoic acid (Cmb) residue. The Ahp residue 
was identified by COSY correlations following the sequen-
tial spin system starting at the α-proton at δ3.79 (H-2Ahp) 
followed by two methylene protons at δ 2.42/1.58 (H-3Ahp), 
another set of methylene protons at δ 1.72/1.58 (H-4Ahp), 
and an oxygenated methine at δ 5.08 (H-5Ahp). The ring 
closure was based on HMBC correlations from the α-
proton at δ 3.79 (H-2Ahp), the methylene protons at δ 2.42 
and 1.58 (2H-3Ahp) and the oxygenated methine proton at 
δ 5.08 (H-5Ahp) to the carbonyl carbon at δ 168.5.  
The Abu structure was based on a COSY correlation be-
tween the methyl protons at δ 1.48 (Me-4Abu) and a vinylic 
methine proton at δ 6.52 (H-3Abu) as well as HMBC corre-
lations from both proton signals to carbon resonances at 
δ 129.8 (C-2Abu) and 162.6 (C-1Abu). The structure of the 
remaining C5H6ClO residue was deduced as follows. 
Long-range COSY correlations between the vinylic me-
thine proton at δ 6.10 (H-4Cmb), the methyl protons at δ 
1.72 (Me-5Cmb) and the methylene protons at δ 2.97 (2H-
2Cmb) gave an unclear picture of the residue structure. 
Additionally, HMBC correlations from all three of these 
proton signals to a quaternary carbon at δ 133.9 (C-3Cmb) 
and a carbonyl signal at δ 168.4 (C-1Cmb) left the position 
of the double bond unresolved as four-bond (4JCH) inter-
actions are occasionally observed in the proximity of dou-
ble bonds. To differentiate between a 4-chloro-3-
methylbut-3-enoic acid and a 4-chloro-3-methyl-2-enoic 
acid residue, a 1,1-ADEQUATE spectrum with non-
uniform sampling (NUS) was recorded which showed a 
two bond correlation from the methylene protons at δ 
2.97 (2H-2Cmb) to the carbonyl signal at δ 168.4 (C-1Cmb), 
thereby confirming this as a 4-chloro-3-methylbut-3-
enoic acid residue. Finally, an NOE correlation between 
the associated amide proton at δ 8.21 (NHAla) and the 
methylene protons at δ 2.97 (2H-2Cmb) helped to confirm 
the identity and location of the residue. The sequence of 
residues was established as Val-N-MeTyr-Phe-Ahp-Abu-
Thr-Ile-Ala-Cmb through HMBC correlations between 
consecutive α-protons to carbonyl carbons of adjacent 
residues together with NOE correlations between α-
protons and amide protons (Figure 2). The ring closure 
between the C-terminal valine and the β-hydroxy group 
of threonine was established based on NOE correlations 
from the valine α-proton at δ 4.65 (H-2Val) to the threo-
nine methine and methyl protons at δ 5.53 (H-3Thr) and δ 
1.21 (Me-3Thr), respectively. 
The second and considerably less abundant new com-
pound isolated from this extract, tutuilamide B (2), 
showed a HR-ESI-MS molecular ion peak at m/z 
1029.4445 [M + Na]+ (calcd for C50H67ClN8O12Na, 
1029.4459, Δ = 1.36 ppm), thus having one less methylene 
unit than 1. Comparison of NMR features for 2 (Table S2) 
showed it to be highly similar in all regards to 1, with the 
primary difference being that the triplet methyl from the 
Ile residue at δ 0.80 (Me-5Ile) in 1 was replaced by an addi-
tional doublet methyl at δ 0.82 (Me-5Val2) in 2, thus reveal-
ing 2 to be the valine analog of 1. 
 
 
Figure 2. Selected NOE correlations for tutuilamide A (1). 
Inset shows selected correlations observed for the Ahp resi-
due. 
The absolute configurations of the amino acid residues 
in both natural products were determined by LC-MS 
analysis of the 1-fluoro-2,4-dinitro-phenyl-5-D-
alanineamide (D-FDAA) derivatives derived from the acid 
hydrolyzate of 1 and 2 (Marfey’s method, Table S3).17 This 
revealed that all of the amino acid residues in both com-
pounds were of L-configuration, as is the case for all other 
cyanopeptolin-like peptides. In addition, PDC oxidation 
followed by acid hydrolysis liberated L-glutamic acid from 
the Ahp residue, as determined by Marfey’s analysis, 
therefore establishing the configuration of C-2Ahp as S. To 
determine the relative stereochemistry between C-2Ahp 
and C-5Ahp in 1, a combination of proton-proton coupling 
constants and NOE correlations was used (Figure 2). The 
relative conformation of the Ahp ring was determined 
based on the H-2Ahp to H-3Ahp coupling constant; a large 
value was observed (3JH-2,H-3a = 12.3 Hz), indicating that 
these two deshielded protons were axially oriented.18 NOE 
correlations between H-2Ahp, H-4aAhp and H-5Ahp as well as 
between H-3aAhp, OHAhp and NHAhp revealed the relative 
configuration of the two stereocenters, and therefore es-
tablished the configuration of C-5Ahp as R. The highly 
comparable NMR data sets for this Ahp residue for com-
pounds 1–3 (see Supporting Information, Tables 1 and 2) 
strongly suggests that they are all of the same relative 
configuration, and likely of the same absolute configura-
tion. The geometry of the Abu olefinic bond was deter-
mined as Z based on an NOE correlation in DMSO-d6 
between the methyl protons at δ1.48 (Me-4Abu) and the 
amide proton at δ 9.23 (NHAbu). Finally, a 1D NOE exper-
iment with selective irradiation of the vinylic proton at δ 
6.07 (in methanol-d4 to avoid overlapping signals with 
OHAhp) established the E geometry of the Cmb residue 
due to a correlation to the methylene protons at δ 3.03 
(2H-2Cmb). 
Subsequently, a third tutuilamide was isolated from a 
Coleofasciculus sp. extract (3). The HR-ESI-MS of tutu-
ilamide C showed a precursor ion at m/z 972.4252 [M + 
Na]+ (calcd for C48H64ClN7O11Na, 972.4255, Δ = 0.31 ppm) 
and the NMR data were highly similar to that of 2, except 
for the lack of the alanine moiety resonances and pos-
sessing an additional methylene in the side-chain (Table 
S2). HMBC, TOCSY and ROESY correlations corroborated 
the same connectivities observed between the amino acid 
residues as for 1 and 2. Because the NMR data of 2 and 3 
were highly similar, we propose that they are of the same 
relative configuration at comparable stereocenters. This 
hypothesis is additionally supported by the observation 
that all Abu and Ahp-containing peptides reported to 
date are composed only of L-amino acids.7–14 
Inhibition of serine proteases with tutuilamide an-
alogs. Studies have shown that Ahp-Abu-containing cy-
clic hexadepsipeptides inhibit serine proteases such as 
elastase by binding to the active site in a substrate-like 
manner. Therefore, 5 µM to 85 pM of 1, 2 and 3 were in-
cubated with porcine pancreatic elastase and potency was 
directly compared to lyngbyastatin 7 (4) and symplostatin 
2. Compounds 1 and 2 were found to be the most potent 
in this group, inhibiting elastase with IC50’s of 1–2 nM 
(Table 2, Figure S2 and S3). Compound 3 and sym-
plostatin 2 had IC50 values of ~5 nM, while 4 was the 
weakest inhibitor with an IC50 of 11.5 nM. 
Elastase is a member of the S1 family of serine proteases 
that forms a double β-barrel structure. Trypsin and chy-
motrypsin are also members of the S1 family and therefore 
we determined if tutuilamide A, B and C can also inhibit 
these structurally related enzymes. When bovine trypsin 
was incubated with up to 20 µM of these compounds, no 
inhibition was detected. This enzyme has a strong prefer-
ence for binding to peptide inhibitors containing basic 
amino acids such as arginine and lysine, both of which are 
absent from these natural products. When incubated with 
chymotrypsin the IC50 values ranged from 542 nM to 1014 
nM. Although the potency of these compounds is consid-
erably weaker for chymotrypsin than elastase, the relative 
potency of the three tutuilamide analogs differs between 
enzymes. Chymotrypsin appears to have a preference for 
valine as found in 2 and 3 over isoleucine found in com-
pound 1, resulting in a 2-fold reduction in potency. This 
inhibition profile is consistent with several other Ahp-
Abu-containing cyclic hexadepsipeptides that preferen-
tially inhibit elastase over chymotrypsin and trypsin.19 
Outside of the S1 family, commonly studied serine pro-
teases are from the S8 family. These enzymes have no 
sequence or structural homology with S1 family serine 
proteases and include the bacterial and fungal subtilisin 
enzymes commonly used in laundry detergents and the 
mammalian kexin family of enzymes.20 When 1 and 2 
were incubated with proteinase K, a representative S8 
protease isolated from the soil fungus Engyodontium al-
bum, we observed IC50s of 103.7 and 87.6 nM, respectively. 
 
 
Table 2: Potency of compounds for select serine proteases following 30 minute incubations 
 IC50 values (nM) with 95% Confidence Interval Values  
Name (Analog Number) Elastase Chymotrypsin Trypsin Proteinase K 
Tutuilamide A (1) 1.18 (0.33 – 1.97) 1014 (853.0 – 1227) >20,000 103.7 (84.6 – 129.2) 
Tutuilamide B (2) 2.05 (1.68 – 2.46) 576.6 (447.0 – 767.3) >20,000 87.6 (65.2 – 122.2) 
Tutuilamide C (3) 4.93 (2.72 – 7.48) 542.0 (445.0 – 671.2) >20,000 >5,000 
Lyngbyastatin 7 (4) 11.50 (9.25 – 14.28) Not Done Not Done 1574 (806.0 to >5,000) 
Symplostatin 2 5.41 (4.30 – 6.69) Not Done Not Done 216.5 (155.2 – 326.0) 
Tutuilamide A-linear (5) 3,994 (2363 – 11,735) Not Done Not Done >5,000 
Tutuilamide A-methyl (6) 1.83 (1.56 – 2.12) Not Done Not Done 98.6 (94.4 – 100.1) 
 
However, 3 had more than a 50-fold weaker inhibition 
for this enzyme (IC50 >5 µM), suggesting that longer pep-
tides have higher potency for this enzyme. When compar-
ing the potency of symplostatin 2, an 8-mer cyclic hexa-
depsipeptide to the 7-mer peptide 4, the IC50 value de-
creased 7.3-fold for the shorter peptide inhibitor. These 
data show that changes in peptide length and amino acid 
composition of these cyclic hexadepsipeptides result in 
differences in potency and selectivity for serine proteases.  
In addition, we determined the cytotoxic activity of 
compounds 1–3 towards the H-460 human lung cancer 
cell line. The compounds show moderate activity with 
IC50s of 0.53 ± 0.04 µM, 1.27 ± 0.21 µM and 4.78 ± 0.45 µM, 
respectively (Figure S1).  
Synthesis of semi-synthetic analogs of 1. A limited 
structure-activity relationship study on tutuilamide A was 
performed to explore the structural features related to the 
elastase and proteinase K inhibitory activity (Scheme 1). 
In the first semi-synthetic analog of 1, the depsipeptide 
ester was hydrolyzed using LiOH/H2O to obtain the acy-
clic analog 5. This analog failed to inhibit proteinase K 
activity at a concentration of 5 µM while potency for elas-
tase was decreased 2,600-fold when compared to the cy-
clic tutuilamide A (1).  
 
 
Scheme 1. Synthesis of semi-synthetic analogs 5 and 6 of 
tutuilamide A (1) 
These data demonstrate the importance of the cyclic 
structure to inhibit these serine proteases. In addition, 
the hemi-aminal moiety in 1 was methylated with metha-
nol in the presence of pyridinium p-toluenesulfonate 
(PPTS) to generate analog 6. This modification is predict-
ed to improve the metabolic stability of the Abu moiety 
without affecting the potency of the compound; indeed, 
analog 6 showed excellent single digit nanomolar potency 
to elastase (Table 3).  
Rationalizing the binding of tutuilamide A to elas-
tase. We next determined the crystal structure of porcine 
pancreatic elastase in complex with 1 in order to compare 
the binding mode of the depsipeptide with related mole-
cules. The complex crystallized in space group P 21 21 21, 
and data was collected to 2.2 Å. The structure was deter-
mined by molecular replacement using the published 
elastase apo structure (PDB ID: 1LVY) as a search model 
(Figure 3A). Full details of the data collection and refine-
ment statistics can be found in Table S4. Compound 1 was 
found to occupy the same binding pocket as lyngbyastatin 
7 (4), explaining the observed identical mode of action of 
tutuilamide A compared to other Abu-bearing cyclic dep-
sipeptides, with the Abu moiety and the N-terminal resi-
dues occupying the S1-S4 pockets (Figure 3B).13,15 Howev-
er, compared to 4, the carbonyl group of the flexible Cmb 
moiety of 1 forms an additional hydrogen bond with the 
backbone amide of Arg217 (Figure 3B and Figure S4). This 
additional interaction could explain the slightly more 
potent inhibitory activity of tutuilamides compared to 
lyngbyastatin 7 in that this interaction would further sta-
bilize the binding of tutuilamide A to the elastase binding 
pocket. 
The potency of semi-synthetic analogs 5 and 6 was 
evaluated in the context of our co-crystal structure. As 
shown for 4, the cyclic core of 1 also forms a network of 
direct and water mediated inter- and intramolecular hy-
drogen bonds (Figure S5). Therefore, one would expect 
any changes to the cyclic nature of these compounds to 
have a negative impact on their potency. This is indeed 
the case as shown by the observed nearly 3,400-fold de-
crease in potency of acyclic analog 5. The hemiaminal 
moiety of 1 is facing a hydrophobic pocket formed by Leu 
63 and Phe 65 (Figure S5). This pocket is large enough to  
 
 
Figure 3. A Cartoon representation of PPE (cyan) in complex with 1 (shown as grey sticks). B Comparison of 1 (grey) and 4 (PDB: 
4GVU; orange) binding to PPE (cyan surface). The side chains of PPE residues Ser216 and Arg217 are shown as sticks. The addi-
tional hydrogen bond found in the PPE-1 complex structure is indicated by a dashed line. 
accommodate methylated analog 6, without resulting in a 
steric clash with the binding pocket (Figure S5). Given the 
size of the pocket, even larger hydrophobic functional 
groups at this position may be accommodated. This could 
result in an enhancement of hydrophobic interactions, 
thereby further stabilizing the compound in the active 
site. However, further optimization of this group must be 
pursued cautiously, as the oxygen atom of the hydroxy or 
methoxy group is involved in intramolecular hydrogen 
bonding with the neighboring residues, and thus facili-
tates the formation of a cis peptide bond (Figure S5). In 
turn, this contributes to the rigidity of the cyclic core 
making these compounds less sensitive to protease activi-
ty.13,15,21,22 
 
CONCLUSION 
Tutuilamides A–C are new representatives of the family 
of Ahp-cyclodepsipeptides (cyanopeptolin-like peptides) 
isolated from Cyanobacteria. They share the cyclic pep-
tide core, including the distinctive 2-amino-2-butenoic 
acid (Abu) residue, with a group of cyclic depsipeptides 
mainly isolated from marine cyanobacteria; however, they 
also contain an unprecedented 4-chloro-but-3-enoic acid 
moiety. The predicted biosynthesis of these new cyclic 
lipopeptides suggests initiation of the pathway by a 
polyketide synthase which produces an intermediate β-
ketobutyrate moiety. This is expected to undergo trans-
formation by a -branch cassette of genes that also intro-
duces a chlorine atom via radical chemistry, as shown in 
the case of jamaicamide A biosynthesis.16  
The new compounds are potent inhibitors of porcine 
pancreatic elastase and fungal proteinase K. Direct com-
parison to the potent elastase inhibitor lyngbyastatin 7 
revealed that the new compounds have 2 to 4-fold in-
creased potency. Structural analysis of tutuilamide A in 
complex with the porcine pancreatic elastase confirms the 
same binding mechanism of lyngbyastatin 7 with an addi-
tional strong hydrogen bond (2.8 Å) between the Cmb 
carbonyl group and the backbone amide group of elastase 
residue R226; this additional hydrogen bond appears to 
stabilize the ligand in the binding pocket and may explain 
the increased potency of tutuilamides A over lyngbyas-
tatin 7. 
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d4, 1H NMR, 13C NMR, 1H-1H COSY, 1H-1H NOESY, 1H-13C 
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